206 related articles for article (PubMed ID: 8383224)
1. The last seven transmembrane and carboxy-terminal cytoplasmic domains of Epstein-Barr virus latent membrane protein 2 (LMP2) are dispensable for lymphocyte infection and growth transformation in vitro.
Longnecker R; Miller CL; Miao XQ; Tomkinson B; Kieff E
J Virol; 1993 Apr; 67(4):2006-13. PubMed ID: 8383224
[TBL] [Abstract][Full Text] [Related]
2. The only domain which distinguishes Epstein-Barr virus latent membrane protein 2A (LMP2A) from LMP2B is dispensable for lymphocyte infection and growth transformation in vitro; LMP2A is therefore nonessential.
Longnecker R; Miller CL; Miao XQ; Marchini A; Kieff E
J Virol; 1992 Nov; 66(11):6461-9. PubMed ID: 1328675
[TBL] [Abstract][Full Text] [Related]
3. Deletion of DNA encoding the first five transmembrane domains of Epstein-Barr virus latent membrane proteins 2A and 2B.
Longnecker R; Miller CL; Tomkinson B; Miao XQ; Kieff E
J Virol; 1993 Aug; 67(8):5068-74. PubMed ID: 8392630
[TBL] [Abstract][Full Text] [Related]
4. The Epstein-Barr virus LMP1 cytoplasmic carboxy terminus is essential for B-lymphocyte transformation; fibroblast cocultivation complements a critical function within the terminal 155 residues.
Kaye KM; Izumi KM; Mosialos G; Kieff E
J Virol; 1995 Feb; 69(2):675-83. PubMed ID: 7815530
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus recombinant molecular genetic analysis of the LMP1 amino-terminal cytoplasmic domain reveals a probable structural role, with no component essential for primary B-lymphocyte growth transformation.
Izumi KM; Kaye KM; Kieff ED
J Virol; 1994 Jul; 68(7):4369-76. PubMed ID: 8207810
[TBL] [Abstract][Full Text] [Related]
6. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking.
Miller CL; Lee JH; Kieff E; Longnecker R
Proc Natl Acad Sci U S A; 1994 Jan; 91(2):772-6. PubMed ID: 8290598
[TBL] [Abstract][Full Text] [Related]
7. The residues between the two transformation effector sites of Epstein-Barr virus latent membrane protein 1 are not critical for B-lymphocyte growth transformation.
Izumi KM; Cahir McFarland ED; Riley EA; Rizzo D; Chen Y; Kieff E
J Virol; 1999 Dec; 73(12):9908-16. PubMed ID: 10559303
[TBL] [Abstract][Full Text] [Related]
8. An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro.
Robertson ES; Tomkinson B; Kieff E
J Virol; 1994 Mar; 68(3):1449-58. PubMed ID: 8107208
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation.
Tomkinson B; Robertson E; Kieff E
J Virol; 1993 Apr; 67(4):2014-25. PubMed ID: 8445720
[TBL] [Abstract][Full Text] [Related]
10. Mutants of Epstein-Barr virus with a selective marker disrupting the TP gene transform B cells and replicate normally in culture.
Kim OJ; Yates JL
J Virol; 1993 Dec; 67(12):7634-40. PubMed ID: 8230482
[TBL] [Abstract][Full Text] [Related]
11. An Epstein-Barr virus that expresses only the first 231 LMP1 amino acids efficiently initiates primary B-lymphocyte growth transformation.
Kaye KM; Izumi KM; Li H; Johannsen E; Davidson D; Longnecker R; Kieff E
J Virol; 1999 Dec; 73(12):10525-30. PubMed ID: 10559372
[TBL] [Abstract][Full Text] [Related]
12. In vivo growth of Epstein-Barr virus transformed B cells with mutations in latent membrane protein 2 (LMP2).
Rochford R; Miller CL; Cannon MJ; Izumi KM; Kieff E; Longnecker R
Arch Virol; 1997; 142(4):707-20. PubMed ID: 9170499
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation.
Cohen JI; Wang F; Kieff E
J Virol; 1991 May; 65(5):2545-54. PubMed ID: 1850028
[TBL] [Abstract][Full Text] [Related]
14. Identification of latent membrane protein 2A (LMP2A) domains essential for the LMP2A dominant-negative effect on B-lymphocyte surface immunoglobulin signal transduction.
Fruehling S; Lee SK; Herrold R; Frech B; Laux G; Kremmer E; Grässer FA; Longnecker R
J Virol; 1996 Sep; 70(9):6216-26. PubMed ID: 8709248
[TBL] [Abstract][Full Text] [Related]
15. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
Tierney RJ; Steven N; Young LS; Rickinson AB
J Virol; 1994 Nov; 68(11):7374-85. PubMed ID: 7933121
[TBL] [Abstract][Full Text] [Related]
16. An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.
Longnecker R; Druker B; Roberts TM; Kieff E
J Virol; 1991 Jul; 65(7):3681-92. PubMed ID: 1710288
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation.
Kaye KM; Izumi KM; Kieff E
Proc Natl Acad Sci U S A; 1993 Oct; 90(19):9150-4. PubMed ID: 8415670
[TBL] [Abstract][Full Text] [Related]
18. The effect of Epstein-Barr virus Latent Membrane Protein 2 expression on the kinetics of early B cell infection.
Wasil LR; Tomaszewski MJ; Hoji A; Rowe DT
PLoS One; 2013; 8(1):e54010. PubMed ID: 23308294
[TBL] [Abstract][Full Text] [Related]
19. Biochemical and genetic studies of Epstein-Barr virus latent membrane protein 2.
Longnecker R
Leukemia; 1994 Apr; 8 Suppl 1():S46-50. PubMed ID: 8152303
[TBL] [Abstract][Full Text] [Related]
20. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
Lee SP; Thomas WA; Murray RJ; Khanim F; Kaur S; Young LS; Rowe M; Kurilla M; Rickinson AB
J Virol; 1993 Dec; 67(12):7428-35. PubMed ID: 7693972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
